Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $34.00

Key Points

• Guggenheim has raised its price target for Maze Therapeutics (NASDAQ:MAZE) from $19.00 to $34.00, indicating a potential upside of 45.92% from the stock's previous close.
• The company is currently rated as a "buy" by multiple brokerages, with an average rating of "Buy" and a consensus target price of $32.67.
• Maze Therapeutics recently reported ($0.77) earnings per share, surpassing analysts' expectations by $0.02, while its stock price opened at $23.30 on Monday.

Maze Therapeutics (NASDAQ:MAZE - Free Report) had its target price boosted by Guggenheim from $19.00 to $34.00 in a report released on Monday, Marketbeat reports. Guggenheim currently has a buy rating on the stock.

A number of other analysts also recently commented on MAZE. HC Wainwright boosted their price objective on shares of Maze Therapeutics from $34.00 to $50.00 and gave the stock a "buy" rating in a report on Friday, September 12th. Wall Street Zen raised shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Wedbush assumed coverage on shares of Maze Therapeutics in a research report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price target for the company. Finally, BTIG Research increased their price objective on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a "buy" rating in a research note on Friday, September 12th. Two investment analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $32.67.

Maze Therapeutics Stock Performance

Shares of NASDAQ:MAZE traded down $0.36 during mid-day trading on Monday, reaching $23.12. 167,657 shares of the company were exchanged, compared to its average volume of 266,213. The firm's 50-day simple moving average is $16.00 and its 200 day simple moving average is $12.59. Maze Therapeutics has a 1 year low of $6.71 and a 1 year high of $25.50.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

Insider Transactions at Maze Therapeutics

In related news, Director Richard H. Scheller sold 20,744 shares of the stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Hedge Funds Weigh In On Maze Therapeutics

A number of large investors have recently bought and sold shares of MAZE. Tower Research Capital LLC TRC boosted its holdings in shares of Maze Therapeutics by 452.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company's stock valued at $57,000 after buying an additional 3,774 shares during the last quarter. Frazier Life Sciences Management L.P. grew its holdings in shares of Maze Therapeutics by 10.6% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company's stock worth $56,040,000 after purchasing an additional 438,274 shares during the last quarter. Engineers Gate Manager LP bought a new stake in shares of Maze Therapeutics during the second quarter worth about $125,000. Bank of America Corp DE grew its holdings in shares of Maze Therapeutics by 33.6% during the second quarter. Bank of America Corp DE now owns 5,782 shares of the company's stock worth $71,000 after purchasing an additional 1,455 shares during the last quarter. Finally, CW Advisors LLC acquired a new position in shares of Maze Therapeutics in the second quarter worth approximately $371,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.